1. Home
  2. NATR vs ADCT Comparison

NATR vs ADCT Comparison

Compare NATR & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nature's Sunshine Products Inc.

NATR

Nature's Sunshine Products Inc.

HOLD

Current Price

$24.95

Market Cap

470.3M

Sector

Health Care

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$4.10

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NATR
ADCT
Founded
1972
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
470.3M
484.4M
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
NATR
ADCT
Price
$24.95
$4.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$21.33
$7.50
AVG Volume (30 Days)
101.0K
812.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
44.90
EPS
0.83
N/A
Revenue
$454,364,000.00
$70,837,000.00
Revenue This Year
$7.30
$14.96
Revenue Next Year
$3.44
$1.06
P/E Ratio
$31.22
N/A
Revenue Growth
2.03
1.84
52 Week Low
$11.01
$1.05
52 Week High
$28.14
$4.80

Technical Indicators

Market Signals
Indicator
NATR
ADCT
Relative Strength Index (RSI) 40.53 51.41
Support Level $13.69 $3.25
Resistance Level $26.96 $4.71
Average True Range (ATR) 0.96 0.25
MACD -0.32 -0.02
Stochastic Oscillator 10.34 29.76

Price Performance

Historical Comparison
NATR
ADCT

About NATR Nature's Sunshine Products Inc.

Natures Sunshine Products Inc is a natural health and wellness company, predominantly engaged in the manufacturing and selling of nutritional and personal care products. It offers products related to Weight management, General health, Cardiovascular, Digestive, Immune, and Personal care. The company operates in four segments namely, Asia which is also its key revenue generating market, Europe, North America, Latin America, and Other.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: